Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) EBITDA Margin (2018 - 2025)

Precision Biosciences (DTIL) has disclosed EBITDA Margin for 8 consecutive years, with 36.57% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 393093.0% to 36.57% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 152.19% through Dec 2025, down 11411.0% year-over-year, with the annual reading at 152.19% for FY2025, 11411.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 36.57% at Precision Biosciences, up from 158976.92% in the prior quarter.
  • The five-year high for EBITDA Margin was 48.39% in Q2 2024, with the low at 158976.92% in Q3 2025.
  • Average EBITDA Margin over 5 years is 18364.59%, with a median of 175.71% recorded in 2022.
  • Peak annual rise in EBITDA Margin hit 393093bps in 2025, while the deepest fall reached -15528335bps in 2025.
  • Over 5 years, EBITDA Margin stood at 484.68% in 2021, then skyrocketed by 76bps to 114.26% in 2022, then tumbled by -85bps to 211.57% in 2023, then plummeted by -1741bps to 3894.36% in 2024, then surged by 101bps to 36.57% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 36.57%, 158976.92%, and 121538.89% for Q4 2025, Q3 2025, and Q2 2025 respectively.